Exelixis (EXEL) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
26 May, 2026Opening remarks and agenda
Meeting called to order by the President and CEO, with key executives and independent auditors present.
Meeting held virtually, allowing stockholders to participate, submit questions, and vote online.
Agenda and rules of conduct provided in the virtual portal; only proposals in the proxy statement to be voted on.
Notice of meeting duly given; quorum established with 90.16% of shares represented.
Board and executive committee updates
Election of 11 directors to serve until the next annual meeting in 2027, with all nominees recommended by the board.
Shareholder proposals
Ratification of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending January 1, 2027.
Amendment and restatement of the 2017 Equity Incentive Plan to increase authorized shares by 2 million.
Advisory approval of named executive officer compensation as disclosed in the proxy statement.
Latest events from Exelixis
- Zanzalintinib targets leadership in CRC and RCC with pivotal trials and robust clinical strategy.EXEL
Stifel 2026 Targeted Oncology Virtual Forum20 May 2026 - CABO and zanza drive growth with strong launches, pivotal trials, and robust commercial execution.EXEL
RBC Capital Markets Global Healthcare Conference 202619 May 2026 - Zanzalintinib and CABOMETYX fuel growth as new studies and pipeline assets target solid tumors.EXEL
Barclays 28th Annual Global Healthcare Conference17 May 2026 - Flexible capital deployment supports CABO and zanza growth, with major trials and launches ahead.EXEL
Bank of America Global Healthcare Conference 202612 May 2026 - Q1 2026 saw 10% revenue growth, strong cabozantinib sales, and zanzalintinib NDA progress.EXEL
Q1 20266 May 2026 - Zanzalintinib advances as a next-gen TKI amid strong growth and expanding oncology pipeline.EXEL
TD Cowen 46th Annual Health Care Conference29 Apr 2026 - Proposal No. 3 requires a majority vote, with abstentions counting against and broker non-votes ignored.EXEL
Proxy filing17 Apr 2026 - Shareholders to vote on directors, auditor, equity plan, and pay amid strong growth and ESG focus.EXEL
Proxy filing15 Apr 2026 - Key votes include director elections, auditor ratification, and an equity plan share increase.EXEL
Proxy filing15 Apr 2026